Table 1.
Comparison of clinical, CT findings, and laboratory data for asymptomatic patients with and without COVID-19 related CT findings
| Patients with CT infiltrates (n = 48) | Patients without CT infiltrates (n = 26) | p value | ||||
|---|---|---|---|---|---|---|
| Number | % | Number | % | |||
| Clinical features | Gender (F) | 31 | 65 | 12 | 46 | 0.198 |
| Smoking habits: current/never/ex | 15/30/3 | 31/63/6 | 6/18/2 | 23/69/8 | 0.741 | |
| Significant past medical history | 12 | 25 | 9 | 35 | 0.635 | |
| Contact with SARS-CoV-2 infected patient | 35 | 73 | 10 | 38 | 0.008* | |
| Avg | SD | Avg | SD | |||
| Age (years) | 54 | 17 | 53 | 21 | 0.954 | |
| Body height (cm) | 162 | 7 | 162 | 8 | 1.000 | |
| Body weight (kg) | 64 | 11 | 63 | 10 | 0.502 | |
| BMI | 24.5 | 3.5 | 23.9 | 3.4 | 0.476 | |
| Body temperature (°C) | 37.0 | 0.7 | 36.6 | 0.3 | 4.12 × 10-4* | |
| Respiratory rate (breaths/min) | 16 | 2 | 16 | 2 | 0.722 | |
| Systolic BP (mmHg) | 137 | 24 | 136 | 22 | 0.964 | |
| Diastolic BP (mmHg) | 92 | 15 | 86 | 10 | 0.038* | |
| Heart rate (beats/min) | 77 | 18 | 76 | 14 | 0.798 | |
| SpO2 (%) | 98 | 1 | 97 | 3.4 | 0.216 | |
| RT-PCR positive period (days) | 10.2 | 3.7 | 11.6 | 5.3 | 0.616 | |
| Laboratory features | BUN (mmol/L) | 4.34 | 1.57 | 5.19 | 1.67 | 0.064 |
| Creatinine (μmol/L) | 71 | 19 | 80 | 22 | 0.141 | |
| AST (IU/L) | 29 | 20 | 25 | 8 | 0.831 | |
| ALT (IU/L) | 28 | 28 | 28 | 23 | 0.738 | |
| T-Bil (μmol/L) | 5.84 | 6.48 | 2.28 | 4.06 | 0.280 | |
| γGTP (IU/L) | 45 | 49 | 32 | 20 | 0.653 | |
| Amylase (IU/L) | 79 | 28 | 85 | 32 | 0.464 | |
| LDH (mmol/L) | 210 | 65 | 179 | 25 | 0.187 | |
| Albumin (g/L) | 41 | 4 | 41 | 10 | 0.218 | |
| CRP (mg/L) | 10.8 | 15.8 | 1.7 | 2.0 | 0.001* | |
| UA (μmol/L) | 305 | 78 | 297 | 56 | 0.735 | |
| PCT (ng/mL) | 0.18 | 0.22 | 0.23 | 0.16 | 0.337 | |
| IgG (mg/L)† | 1338 | 327 | 1400 | 325 | 0.586 | |
| IgA (mg/L)† | 271 | 135 | 300 | 131 | 0.517 | |
| IgM (mg/L)† | 88 | 39 | 84 | 43 | 0.419 | |
| KL-6 (U/mL)† | 337 | 173 | 227 | 71 | 0.021* | |
| RBC (× 1012/L) | 5 | 1 | 5 | 1 | 0.260 | |
| Hemoglobin (g/L) | 141 | 17 | 140 | 20 | 0.610 | |
| WBC (× 109/L) | 5.37 | 1.76 | 6.59 | 1.98 | 0.018* | |
| Platelet (× 109/L) | 224 | 71 | 240 | 70 | 0.385 | |
| Neutrophil (%) | 62.9 | 11.0 | 64.5 | 8.9 | 0.507 | |
| Lymphocyte (%) | 28.3 | 9.3 | 26.7 | 8.2 | 0.458 | |
| Monocyte (%) | 7.1 | 3.0 | 6.3 | 2.3 | 0.340 | |
| Eosinophil (%) | 1.4 | 1.7 | 1.8 | 1.7 | 0.065 | |
| APTT (time) | 29 | 5 | 30 | 4 | 0.215 | |
| APTT (std) | 28 | 0 | 28 | 0 | 0.284 | |
| PT (%) | 105 | 16 | 97 | 7 | 0.095 | |
| PT (INR) | 0.97 | 0.08 | 1.01 | 0.05 | 0.020* | |
Abbreviations: CT, computed tomography; γGTP, gamma-glutamyl transferase; T-Bil, total bilirubin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; SpO2, capillary hemoglobin oxygen saturation; BUN, blood urea nitrogen; CRP, C-reactive protein; UA, uric acid; PCT, procalcitonin; Ig, immunoglobulin; HU, Hounsfield units; LDH, lactate dehydrogenase; PT, prothrombin time; PT (INR), prothrombin time calculated as international normalized ratio; RBC, red blood cell count; WBC, white blood cell count; Avg, average; SD, standard deviation
*p < 0.05
†Values were available for Tokyo, Japan, cohort only